Expert consensus on treatment for stage III non‐small cell lung cancer
Yi‐Long Wu(Guangdong General Hospital), Yun Fan(Zhejiang Cancer Hospital), Fang Wu(Central South University), Jianya Zhou(Zhejiang University), Yukun Kuang(Sun Yat-sen University), Haihong Yang(First Affiliated Hospital of Guangzhou Medical University), Yu Yao(First Affiliated Hospital of Xi'an Jiaotong University), Buhai Wang(Northern Jiangsu People's Hospital), Weineng Feng(First People's Hospital of Foshan), Chengzhi Zhou(First Affiliated Hospital of Guangzhou Medical University), Jiuwei Cui(Jilin University), Lizhu Lin(First Affiliated Hospital of Guangzhou University of Chinese Medicine), Chao Cheng(Sun Yat-sen University), Ying Cheng(Jilin Province Tumor Hospital), Ming Zhou(Guangzhou Medical University Cancer Hospital), Jian Zhao(ShanghaiTech University), Jiayan Wu(Hong Kong Baptist University), Chengping Hu(Xiangya Hospital Central South University), Shaodong Hong(Sun Yat-sen University), Xiaolong Yan(Air Force Medical University), Xue‐Ning Yang(Guangdong Academy of Medical Sciences), Wenmei Su(Guangdong Medical College), Nong Yang(Hunan Cancer Hospital), Xiaorong Dong(Huazhong University of Science and Technology), Wen‐Zhao Zhong(Guangdong Academy of Medical Sciences), Binchao Wang(Northern Jiangsu People's Hospital), Lin Wu(Materials Systems (United States)), Yan Huang(Sun Yat-sen University), Chun Chen(Fujian Medical University), Lifeng Wang(Nanjing Drum Tower Hospital), Li Zhang(Sun Yat-sen University), Jie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jingjing Liu(Jilin Province Tumor Hospital), Yong Song(Nanjing General Hospital of Nanjing Military Command), Si‐Yang Liu(Guangdong Academy of Medical Sciences), Jie Lin(Kunming Medical University), Hui Guo(Chinese Academy of Sciences), Jin‐Ji Yang(Southern Medical University), Rongrong Chen(Annoroad Gene Technology (China)), Qinghua Zhou(Sichuan Cancer Hospital), Rui Ma(Liaoning Cancer Hospital & Institute), Yongchang Zhang(Central South University), Jia‐Tao Zhang(Guangdong Academy of Medical Sciences), Hongxu Liu(Sun Yat-sen University), Yingying Du(Anhui Medical University), Jia Hu(Wuhan University of Science and Technology), Xueping Quan(Shanghai CASB Biotechnology (China)), Yang Shao, Huijuan Wang(Zhengzhou University), Shun Lü(Shanghai Jiao Tong University)
Cited by 18
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k